Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amy L Clem

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Gene|December 4, 2003
Characterization of the role of Sp1 and NF-Y in differential regulation of PTTG/securin expression in tumor cellsAmy L Clem, Tariq Hamid, Sham S Kakar
Neoplasia (New York, N.Y.)|February 28, 2007
Depletion of ascorbic acid restricts angiogenesis and retards tumor growth in a mouse modelSucheta Telang, Amy L Clem, John W Eaton, et al.
Virology Journal|June 30, 2007
Virus detection and identification using random multiplex (RT)-PCR with 3'-locked random primersAmy L Clem, Jonathan Sims, Sucheta Telang, et al.
Journal of Translational Medicine|May 18, 2012
Small molecule inhibition of 6-phosphofructo-2-kinase suppresses t cell activationSucheta Telang, Brian F Clem, Alden C Klarer, et al.
The Journal of Biological Chemistry|February 12, 2014
Estradiol stimulates glucose metabolism via 6-phosphofructo-2-kinase (PFKFB3)Yoannis Imbert-Fernandez, Brian F Clem, Julie O'Neal, et al.
The Journal of Biological Chemistry|May 29, 2009
Nuclear targeting of 6-phosphofructo-2-kinase (PFKFB3) increases proliferation via cyclin-dependent kinasesAbdullah Yalcin, Brian F Clem, Alan Simmons, et al.
Journal of Translational Medicine|March 13, 2008
Transient T cell depletion causes regression of melanoma metastasesMary Ann Rasku, Amy L Clem, Sucheta Telang, et al.
Molecular Cancer Therapeutics|May 16, 2013
Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancerBrian F Clem, Julie O'Neal, Gilles Tapolsky, et al.
Molecular and Cellular Biochemistry|May 17, 2020
PFKFB2 regulates glycolysis and proliferation in pancreatic cancer cellsSelahattin C Ozcan, Aybike Sarioglu, Tugba H Altunok, et al.
BMC Cancer|December 15, 2011
Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanomaSucheta Telang, Mary Ann Rasku, Amy L Clem, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Gene|December 4, 2003
Characterization of the role of Sp1 and NF-Y in differential regulation of PTTG/securin expression in tumor cellsAmy L Clem, Tariq Hamid, Sham S Kakar
Neoplasia (New York, N.Y.)|February 28, 2007
Depletion of ascorbic acid restricts angiogenesis and retards tumor growth in a mouse modelSucheta Telang, Amy L Clem, John W Eaton, et al.
Virology Journal|June 30, 2007
Virus detection and identification using random multiplex (RT)-PCR with 3'-locked random primersAmy L Clem, Jonathan Sims, Sucheta Telang, et al.
Journal of Translational Medicine|May 18, 2012
Small molecule inhibition of 6-phosphofructo-2-kinase suppresses t cell activationSucheta Telang, Brian F Clem, Alden C Klarer, et al.
The Journal of Biological Chemistry|February 12, 2014
Estradiol stimulates glucose metabolism via 6-phosphofructo-2-kinase (PFKFB3)Yoannis Imbert-Fernandez, Brian F Clem, Julie O'Neal, et al.
The Journal of Biological Chemistry|May 29, 2009
Nuclear targeting of 6-phosphofructo-2-kinase (PFKFB3) increases proliferation via cyclin-dependent kinasesAbdullah Yalcin, Brian F Clem, Alan Simmons, et al.
Journal of Translational Medicine|March 13, 2008
Transient T cell depletion causes regression of melanoma metastasesMary Ann Rasku, Amy L Clem, Sucheta Telang, et al.
Molecular Cancer Therapeutics|May 16, 2013
Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancerBrian F Clem, Julie O'Neal, Gilles Tapolsky, et al.
Molecular and Cellular Biochemistry|May 17, 2020
PFKFB2 regulates glycolysis and proliferation in pancreatic cancer cellsSelahattin C Ozcan, Aybike Sarioglu, Tugba H Altunok, et al.
BMC Cancer|December 15, 2011
Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanomaSucheta Telang, Mary Ann Rasku, Amy L Clem, et al.
Pageof 1